Is retatrutide legal? What the FDA, Lilly and the courts say about buying it in 2026

Is retatrutide legal?

Not to buy, sell or use outside Lilly's own programs. Retatrutide is an investigational drug that no regulator anywhere has approved, and Eli Lilly, which makes it, says it cannot legally be sold or marketed for human use. FDA says it cannot be compounded either. The legal routes are a clinical trial or narrow expanded access.

The short answer is no legal way to buy it in the United States as of November 2026. Retatrutide is an investigational drug (one still being tested in clinical trials, not yet approved for sale) made by Eli Lilly. It works on the receptors for three gut hormones, GIP, GLP-1 and glucagon, which is why it is called a triple agonist [2]. Lilly's own description of it ends with a plain sentence: it is an investigational molecule that cannot be legally sold or marketed for human use [2].

It is not approved anywhere else either. In August 2026 Lilly said that no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world, and that it cannot be sold to consumers [3]. FDA lists retatrutide among the drugs that cannot be used in compounding (a pharmacy making its own version) under federal law, and notes it is not a component of any FDA-approved drug and has not been found safe and effective for any condition [1].

That leaves every vial sold online, by a clinic or through a direct message outside the law's routes. The sections below take each way people try to get it, a pharmacy, a "research use only" vendor, an import, and say what the sources show about each, and then the two routes that are legal.

Is retatrutide FDA approved?

No. Retatrutide is still in phase 3 trials, and as of early November 2026 we found no report that Lilly had submitted it to FDA. In July 2026 Lilly said it plans to file in the first quarter of 2027. Approval can only follow FDA's review of that file, so no prescription version exists yet.

Retatrutide is in phase 3 clinical trials (the last stage of testing before a company asks for approval) for obesity, type 2 diabetes and related conditions [3]. Lilly announced positive results from two more of those trials, TRIUMPH-2 and TRIUMPH-3, on July 23, 2026 [2]. Our guide to the TRIUMPH trial results covers what they found.

Positive trials are not approval. In the same release Lilly said it is completing the chemistry, manufacturing and controls package that a biologics license application (the file a company submits to FDA to ask for approval) requires, and plans to submit retatrutide in Q1 2027 [2]. A medical news report on Lilly's August announcement put it the same way: retatrutide has not yet been reviewed by the FDA [6]. We found no report of a submission as of early November 2026.

So there is no FDA-approved retatrutide product, no label, and no brand name a doctor can prescribe [3]. Any product that presents itself as one is, at best, something else.

Can a pharmacy compound retatrutide?

No. FDA says retatrutide cannot be used in compounding under federal law. A pharmacy may compound only from ingredients with a USP monograph, ingredients of an approved drug or ingredients on an FDA list, and retatrutide meets none of those. FDA has warned telehealth firms, ingredient distributors and outsourcing facilities over it.

Compounding is how some semaglutide and tirzepatide reached patients during the shortages, so it is a natural question. For retatrutide the answer is a flat no, and FDA spelled out why in a September 9, 2025 warning letter (a formal notice that FDA considers a company to be breaking the law) to a seller called GLP-1 Solution [4].

Federal law gives two compounding routes. A state-licensed pharmacy under section 503A may compound from a bulk ingredient only if it has a USP or NF monograph (an official quality standard), is a component of an approved drug, or appears on FDA's 503A bulks list [4]. FDA wrote that retatrutide is not the subject of an applicable monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list [4]. A large outsourcing facility under section 503B needs the ingredient on the 503B bulks list or the drug on the shortage list, and retatrutide is on neither [4]. With no exemption, FDA called the seller's compounded retatrutide unapproved new drugs and misbranded drugs [4].

FDA's current page repeats the rule and lists who it has warned: telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers; active ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders; and outsourcing facilities for repackaging retatrutide [1]. A clinic or pharmacy offering "compounded retatrutide" is offering something the law has no route for.

Is research use only retatrutide legal?

Not when it is sold for people to use. FDA has warned companies selling retatrutide labeled "for research purposes" or "not for human consumption" directly to consumers with dosing instructions, calling them illegally sold unapproved drugs. FDA judges a product by its intended use, so a research label does not change what the seller is doing.

A lot of the retatrutide sold online is labeled "research use only". FDA's position is that the label does not decide the question. It has warned companies that illegally sold unapproved drugs containing retatrutide and other GLP-1 drugs falsely labeled "for research purposes" or "not for human consumption", products that were sold directly to consumers for human use with dosing instructions [1]. It urges consumers not to buy them, because they are of unknown quality and may be harmful [1].

The warning letter to Summit Research Peptides, dated December 10, 2024, shows how FDA reaches that conclusion [5]. The seller's labels read "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY", yet FDA wrote that evidence from its websites established that the products were intended to be drugs for human use [5]. The evidence was the seller's own copy, such as a retatrutide page describing a drug that regulates appetite and blood sugar and a promising approach for obesity and diabetes treatment [5]. On that basis FDA called the retatrutide product an unapproved new drug [5].

That is the line to watch. A vendor that tells you what the vial does in your body, how much to inject or how fast you will lose weight is describing a drug for human use, whatever the label says. Our guide to vetting research peptides covers what a certificate of analysis can and cannot tell you about a vial like this.

Who is being sued, and is the buyer at risk?

The actions in our sources target sellers. In August 2026 Lilly filed six lawsuits against compounding pharmacies, med spas and online sellers, and said it had referred more than 200 people and businesses to authorities. That does not make buying lawful: importing unapproved drugs is generally prohibited, and shipments get intercepted.

On August 12, 2026 Lilly announced six lawsuits against U.S. sellers of retatrutide, including compounding pharmacies, medical spas and online sellers that it says falsely claim their drugs are for "research-use only" when they are intended for human use [3]. The named defendants include Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide [3]. Lilly also said it had referred more than 200 individuals and entities to FDA, the Department of Justice, state attorneys general, law enforcement and licensing boards, and reported more than 14,000 websites, ads, posts and listings marketing retatrutide in over 100 countries [3].

None of the FDA letters or lawsuits we read is aimed at an individual buyer. That is not the same as a purchase being legal. FDA's letter to GLP-1 Solution reminded the seller that the receipt in interstate commerce of misbranded drugs, and the delivery of them, is also a violation of the law [4]. And much of the supply comes from abroad: Lilly says black-market product is frequently made by unregulated foreign manufacturers [3].

Importing is the weak point. Under current law, the importation of unapproved new drugs is generally prohibited, and the law does not generally permit individuals to import prescription drugs for their own use [8]. FDA's personal importation policy is discretion, not a right: it has generally allowed a 90-day supply of an unapproved drug only where effective treatment is not available in the United States, the condition is serious, the drug is not an unreasonable risk and it is not being commercialized [8]. Approved obesity drugs exist in the United States, so a mail-order research vial is a poor fit for that policy. Reuters reported, as quoted by a Canadian outlet, that U.S. Customs and Border Protection intercepted more than 1,400 shipments of illicit obesity and diabetes drugs in July 2026, nearly 90,000 vials [11].

How to get retatrutide legally

There are two legal routes before approval: enrolling in a Lilly clinical trial, or pre-approval expanded access, which a treating physician requests for one patient. Expanded access is for adults with a BMI of at least 35, two or more serious obesity-related complications and obesity that persists despite approved therapy, who cannot join a trial.

The first route is a clinical trial. Lilly's phase 3 program studies retatrutide in obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes and other conditions [2]. Trials that are recruiting are listed on ClinicalTrials.gov, and the study team decides who is eligible. Participants receive the drug, or a placebo, under the protocol, which is the setting the law intends for an investigational drug.

The second route is expanded access (sometimes called compassionate use: an investigational drug given to one patient outside a trial). Lilly registered a pre-approval expanded access program for retatrutide in June 2026 [7]. It is narrow by design. A patient must be 18 or older, have a BMI (body mass index, weight relative to height) of 35 or more despite the highest available dose of approved weight-management therapy, have two or more serious or life-threatening obesity-related complications, and be unable to join an ongoing trial [7]. Requests are started by the treating physician, and patients are told to go through their physician rather than contact Lilly directly [7].

Neither route is a shop. Both put the drug under a study protocol or a physician's request. For everyone else, the approved GLP-1 drugs are the legal option today, and our retatrutide course covers how the drug works and what its trials found while it waits for review.

Is retatrutide legal in the UK or Canada?

No, in both. The UK medicines regulator says retatrutide is not authorised there and that anything sold as retatrutide outside legitimate clinical trials is supplied illegally. Lilly Canada says it is not approved by Health Canada and cannot be lawfully sold to consumers, and Canadian border officers detain unapproved prescription drugs.

In the United Kingdom, the MHRA (the Medicines and Healthcare products Regulatory Agency, the UK drug regulator) has been direct. In a release dated 15 October 2026 it said retatrutide has not been authorised for use in the UK and that products sold as retatrutide outside legitimate clinical trials are being supplied illegally [9]. The same release describes a raid on October 14 in which more than 12,000 fake retatrutide and tirzepatide pens were seized in Birmingham, along with packaging for around 30,000 more [9]. The MHRA told a pharmacy trade publication that retatrutide cannot be legally supplied outside ongoing clinical trials [10].

In Canada, Lilly Canada said in August 2026 that retatrutide has not been approved for human use by Health Canada or any other regulator, and that it cannot be lawfully sold to consumers in Canada or elsewhere [11]. The Canada Border Services Agency said it detains unapproved prescription drugs and refers them to Health Canada, which decides whether they can enter, and that inadmissible goods may be removed or seized [11].

We did not check every country, and rules differ. The pattern in the sources we read is the same, though: the drug is approved nowhere, so no country we checked has a legal retail route for it.